World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Tobin C. Schilke net worth and biography

Tobin Schilke Biography and Net Worth

CFO & Principal Accounting Officer of Revance Therapeutics

Tobin C. Schilke serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since November 2018. Mr. Schilke served as Chief Financial Officer of Achaogen, Inc. from July 2016 through October 2018. From 2002 to June 2016, Mr. Schilke served in roles of increasing responsibility at the Roche Group (including Genentech), a pharmaceutical company, including serving as Finance Director and Company Director of Roche Products Limited in the United Kingdom from August 2014 to June 2016 and serving as Director of Genentech's Commercial Finance BioOncology Business Unit from September 2012 to August 2014. Mr. Schilke holds a B.S. from Lafayette College. a M.S. from the University of California, Berkeley and an M.B.A. from Cornell University's Johnson Graduate School of Management.

How old is Tobin C. Schilke?: Mr. Schilke is currently 49 years old. There are 3 older executives and no younger executives at Revance Therapeutics. The oldest executive at Revance Therapeutics is Mr. Mark J. Foley, CEO & Director, who is 59 years old. Learn More on Tobin C. Schilke's age.
How do I contact Tobin C. Schilke?: The corporate mailing address for Mr. Schilke and other Revance Therapeutics executives is 7555 GATEWAY BLVD., NEWARK CA, 94560. Revance Therapeutics can also be reached via phone at (615) 724-7755 and via email at [email protected]. Learn More on Tobin C. Schilke's contact information.
Has Tobin C. Schilke been buying or selling shares of Revance Therapeutics?: Tobin C. Schilke has not been actively trading shares of Revance Therapeutics during the last quarter. Learn More on Tobin C. Schilke's trading history.
Who are Revance Therapeutics' active insiders?: Revance Therapeutics' insider roster includes Mark Foley (CEO), Dwight Moxie (SVP), Aubrey Rankin (Insider), Angus Russell (Director), and Tobin Schilke (CFO & Principal Accounting Officer ). Learn More on Revance Therapeutics' active insiders.
Are insiders buying or selling shares of Revance Therapeutics?: In the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 264,745 shares worth more than $7,128,621.54. The most recent insider tranaction occured on April, 16th when insider Erica Jordan sold 2,392 shares worth more than $9,089.60. Insiders at Revance Therapeutics own 5.1% of the company. Learn More about insider trades at Revance Therapeutics.
Information on this page was last updated on 4/16/2024.

Tobin C. Schilke Insider Trading History at Revance Therapeutics

Tobin C. Schilke Buying and Selling Activity at Revance Therapeutics

Revance Therapeutics Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Today's Range

Now: $3.25

$3.23

$3.50

50 Day Range

MA: $5.08

$3.57

$7.14

2 Week Range

Now: $3.25

$3.23

$37.98

Volume

1,159,259 shs

Average Volume

1,777,866 shs

Market Capitalization

$338.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

World’s biggest multibillionaire investor is buying THIS by the ton [picture]

From Stansberry Research | Ad

Click here to find out what to do.